TABLE 2.

Priority levels for chemotherapy ^a

Priority	Treatment	Examples
Level 1	Curative therapy with a high (>50%) chance of success	Chemotherapy for germ cell and gestational trophoblastic tumors. Concurrent chemoradiation for cervical cancer
Level 2	Curative therapy with an intermediate (20%–50%) chance of success	Chemotherapy for women with high‐grade serous or endometrioid ovarian cancer, including those with extrapelvic ovarian cancer. Maintenance bevacizumab was discouraged, maintenance with PARP inhibitors was promoted for BRCA patients
Level 3	Curative therapy or adjuvant therapy with 10%–20% chance of success, or noncurative treatment with a >50% chance of 1‐year survival prolongation	Platinum sensitive relapse; advanced, high‐grade endometrial cancer; however, endocrine treatment may be an appropriate alternative for many other endometrial cases
Level 4	Curative therapy with a low (0%–10%) chance of success. Noncurative therapy with an intermediate (15%–50%) chance of more than 1‐year life extension	Chemotherapy for first recurrence of cervical and endometrial cancer (good performance status), or advanced previously untreated disease. Some women with platinum‐sensitive relapsed ovarian cancer
Level 5	Noncurative therapy with a high (more than 50%) chance of palliation/temporary tumor control but less than 1‐year life extension	Chemotherapy for platinum‐resistant ovarian cancer and recurrent endometrial cancer
Level 6	Noncurative therapy with an intermediate (15%–50%) chance of palliation/temporary tumor control and <1‐year life extension	Chemotherapy for metastatic or recurrent cervical cancer or endometrial cancer in second recurrence

^a Source: NICE. ³⁵